MA51914A - Formes posologiques et procédés pour obtenir du bupropion énantiomériquement enrichi ou pur - Google Patents
Formes posologiques et procédés pour obtenir du bupropion énantiomériquement enrichi ou purInfo
- Publication number
- MA51914A MA51914A MA051914A MA51914A MA51914A MA 51914 A MA51914 A MA 51914A MA 051914 A MA051914 A MA 051914A MA 51914 A MA51914 A MA 51914A MA 51914 A MA51914 A MA 51914A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- dosage forms
- enantiomerically enriched
- pure bupropion
- obtaining enantiomerically
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634718P | 2018-02-23 | 2018-02-23 | |
| US201962794469P | 2019-01-18 | 2019-01-18 | |
| US201962809480P | 2019-02-22 | 2019-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51914A true MA51914A (fr) | 2020-12-30 |
Family
ID=67688503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051914A MA51914A (fr) | 2018-02-23 | 2019-02-25 | Formes posologiques et procédés pour obtenir du bupropion énantiomériquement enrichi ou pur |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP3755312A4 (es) |
| JP (3) | JP2021513998A (es) |
| KR (2) | KR20230075531A (es) |
| CN (1) | CN112087999A (es) |
| AU (2) | AU2019223187B2 (es) |
| BR (1) | BR112020017179A2 (es) |
| CA (1) | CA3092076A1 (es) |
| CL (1) | CL2020002166A1 (es) |
| CR (1) | CR20200415A (es) |
| EC (1) | ECSP20060179A (es) |
| IL (1) | IL276871A (es) |
| MA (1) | MA51914A (es) |
| MX (2) | MX2020008704A (es) |
| NI (1) | NI202000056A (es) |
| NZ (1) | NZ767378A (es) |
| PE (1) | PE20211752A1 (es) |
| SG (1) | SG11202008056SA (es) |
| WO (1) | WO2019165379A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11291639B2 (en) | 2018-09-20 | 2022-04-05 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660274B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660273B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| AU2020349419B2 (en) * | 2019-09-20 | 2023-11-02 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999038502A1 (en) * | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Pharmaceutical uses of optically pure (+)-bupropion |
| US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| PL196544B1 (pl) * | 2003-08-08 | 2008-01-31 | Biovail Lab Int Srl | Tabletka o zmodyfikowanym uwalnianiu |
| WO2012118562A1 (en) * | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
| US9198905B2 (en) * | 2013-11-05 | 2015-12-01 | Antecip Bioventures Ii Llc | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
| US10080727B2 (en) * | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US9474731B1 (en) * | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| WO2015095713A1 (en) * | 2013-12-20 | 2015-06-25 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
-
2019
- 2019-02-25 WO PCT/US2019/019445 patent/WO2019165379A1/en unknown
- 2019-02-25 AU AU2019223187A patent/AU2019223187B2/en active Active
- 2019-02-25 KR KR1020237017449A patent/KR20230075531A/ko not_active IP Right Cessation
- 2019-02-25 MA MA051914A patent/MA51914A/fr unknown
- 2019-02-25 MX MX2020008704A patent/MX2020008704A/es unknown
- 2019-02-25 SG SG11202008056SA patent/SG11202008056SA/en unknown
- 2019-02-25 PE PE2020001272A patent/PE20211752A1/es unknown
- 2019-02-25 CN CN201980026874.5A patent/CN112087999A/zh active Pending
- 2019-02-25 NZ NZ767378A patent/NZ767378A/en unknown
- 2019-02-25 BR BR112020017179-4A patent/BR112020017179A2/pt unknown
- 2019-02-25 KR KR1020207027256A patent/KR20210003091A/ko active Application Filing
- 2019-02-25 EP EP19756920.5A patent/EP3755312A4/en active Pending
- 2019-02-25 CR CR20200415A patent/CR20200415A/es unknown
- 2019-02-25 JP JP2020544420A patent/JP2021513998A/ja active Pending
- 2019-02-25 CA CA3092076A patent/CA3092076A1/en active Pending
-
2020
- 2020-08-20 MX MX2023009281A patent/MX2023009281A/es unknown
- 2020-08-21 NI NI202000056A patent/NI202000056A/es unknown
- 2020-08-21 CL CL2020002166A patent/CL2020002166A1/es unknown
- 2020-08-23 IL IL276871A patent/IL276871A/en unknown
- 2020-09-23 EC ECSENADI202060179A patent/ECSP20060179A/es unknown
-
2022
- 2022-06-27 AU AU2022204521A patent/AU2022204521A1/en active Pending
- 2022-08-04 JP JP2022124557A patent/JP2022153638A/ja active Pending
-
2024
- 2024-03-15 JP JP2024041381A patent/JP2024075655A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ767378A (en) | 2024-03-22 |
| EP3755312A4 (en) | 2022-03-16 |
| IL276871A (en) | 2020-10-29 |
| NI202000056A (es) | 2021-01-11 |
| KR20210003091A (ko) | 2021-01-11 |
| PE20211752A1 (es) | 2021-09-06 |
| AU2022204521A1 (en) | 2022-07-21 |
| AU2019223187B2 (en) | 2022-07-28 |
| ECSP20060179A (es) | 2020-12-31 |
| CR20200415A (es) | 2021-02-03 |
| CN112087999A (zh) | 2020-12-15 |
| JP2022153638A (ja) | 2022-10-12 |
| EP3755312A1 (en) | 2020-12-30 |
| KR20230075531A (ko) | 2023-05-31 |
| JP2021513998A (ja) | 2021-06-03 |
| JP2024075655A (ja) | 2024-06-04 |
| CL2020002166A1 (es) | 2020-10-23 |
| WO2019165379A1 (en) | 2019-08-29 |
| MX2020008704A (es) | 2020-12-07 |
| MX2023009281A (es) | 2023-08-17 |
| CA3092076A1 (en) | 2019-08-29 |
| SG11202008056SA (en) | 2020-09-29 |
| AU2019223187A1 (en) | 2020-09-17 |
| BR112020017179A2 (pt) | 2020-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51914A (fr) | Formes posologiques et procédés pour obtenir du bupropion énantiomériquement enrichi ou pur | |
| DK3551622T3 (da) | Modulator af transmembrankonduktansregulator af cystisk fibrose, farmaceutiske sammensætninger, behandlingsfremgangsmåder og fremgangsmåde til fremstilling af modulatoren | |
| DK3445388T3 (da) | Materialer og fremgangsmåder til behandling af hæmoglobinopatier | |
| MA43129A (fr) | Procédés de traitement de la douleur ou de la fièvre au moyen de dimères d'acétaminophène pharmaceutiquement actifs liés par l'intermédiaire de groupes hydroxyle phénoliques | |
| MA50849A (fr) | Substances et procédés pour le traitement d'hémoglobinopathies | |
| DK3347014T3 (da) | Fremgangsmåder til diagnosticering og behandling af Tourettes syndrom | |
| DE102018102542A8 (de) | Vorrichtung zur Handhabung von Fluiden sowie Verfahren zur Herstellung derselben | |
| MA41380A (fr) | Structure en forme de plaque, réservoir et procédé | |
| EP3500248A4 (en) | METHOD AND APPARATUS FOR MANUFACTURING FIBROUS DOSAGE FORMS | |
| GB2576346B (en) | Water purifying apparatus and method | |
| MA45725A (fr) | Structure en forme de plaque, réservoir et procédé | |
| DK3529234T3 (da) | Forbindelser, fremgangsmåde til opnåelse af forbindelserne, farmaceutisk sammensætning, anvendelse af forbindelserne og fremgangsmåde til behandling af psykiatriske lidelser og/eller søvnforstyrrelser | |
| MA52960A (fr) | Compositions et procédés pour la réduction ou le traitement de la fibrose | |
| MA43758A (fr) | Procédés pour déterminer le dosage d'un agent thérapeutique et traitements associés | |
| DK3613281T3 (da) | Apparat til ostefremstilling | |
| SI3773615T1 (sl) | Tekoča sestava za uporabo pri zdravljenju sluznice orofaringealno- laringealno-ezofagealnega trakta | |
| MA49651A (fr) | Compositions et procédés pour traiter des maladies associées à un défaut d'empreinte | |
| DE112018000064A5 (de) | Transporteinrichtung sowie Verfahren und Vorrichtung zur Herstellung der Transporteinrichtung | |
| DE112019003634T8 (de) | Optoelektronisches bauelement und das verfahren zur herstellung eines optoelektronischen bauelements | |
| ITUB20151800A1 (it) | Metodo e apparato per l'acquisizione di radiografie panoramiche e radiografie volumetriche cbct | |
| GB2578272B (en) | Apparatus and method for the production of solid dosage forms | |
| MA55531A (fr) | Procédés pour le traitement de béta-thalassémie | |
| DK3914258T3 (da) | Sammensætning til behandling af periodontitis og regeneration af interdental papi | |
| GB201908229D0 (en) | Microneedles and methods for the manufacture thereof | |
| DE112017005430A5 (de) | Flüssigkeitsreinigungselement, Flüssigkeitsreinigungssystem und Verfahren zur Herstellung eines Flüssigkeitsreinigungselements |